文献速递血栓与止血

癌症相关血栓抗凝依从性:低分子肝素与直接口服抗凝药比较

Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
PubMed 文献 · J Thromb Haemost · 2020-11-21

经倾向性匹配后两组各1128例,DOAC组中位治疗持续时间为116天,LMWH组为34天;

要点

  • DOAC组中位治疗持续时间116天,长于LMWH组的34天。
  • 以PDC≥80%定义依从性时,DOAC与LMWH组依从率无显著差异。
  • 以PDC≥95%定义时,LMWH组依从比例高于DOAC组(81% vs 73%)。

核心结论

  • 患者使用DOAC的持续时间长于LMWH,但以PDC≥80%定义时两组用药依从性相似。

研究设计与样本

  • 经倾向性匹配后DOAC组与LMWH组各1128例。

主要发现

  • DOAC组中位治疗持续时间为116天,LMWH组为34天。
  • 两组平均PDC差异相似。
  • LMWH组平均处方共付费用高于DOAC组(均值153.61美元 vs 40.67美元;标准差306.74 vs 33.11)。

关键数值与推荐

  • 用药依从性分别以PDC≥80%、PDC≥95%及平均PDC比较。
  • PDC计算自抗凝处方日期至抗凝药更换、停止或研究结束。

临床怎么用

  • 临床选择抗凝方案时需兼顾持续性与依从性,DOAC持续性更长但高依从阈值下LMWH依从比例更高。
  • 处方共付费用差异可能影响抗凝药选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials It is not clear if patients are less adherent to low molecular weight heparin (LMWH) compared to direct oral anticoagulants (DOACs) for cancer-associated thrombosis (CAT). We evaluated medication adherence among two propensity-matched groups of patients with CAT by comparing the proportion of days covered (PDC). Median treatment persistence on DOACs was more than 80 days longer than LMWH. Medication adherence was high (~95%) and was similar with LMWH compared to DOACs. ABSTRACT: Background Low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) are used to treat cancer-associated thrombosis (CAT). It is not clear if patients are less adherent to LMWH compared to DOACs. Objectives To compare medication persistence and adherence between LMWH and DOACs. Patients/Methods We analyzed Optum's de-identified Clinformatics® Data Mart Database of privately insured adults with cancer diagnosed between January 2009 and October 2015 who were undergoing chemotherapy, immunotherapy, targeted or hormonal therapies; developed CAT; and were treated with an outpatient anticoagulant. The proportion of days covered (PDC) was calculated from the date of anticoagulant prescription until the anticoagulant was switched, stopped, or the study end. Medication adherence was defined as PDC ≥ 80%, ≥95%, and by comparing the mean PDC. Results Two propensity-matched groups of 1128 patients were identified. Patient persistence was higher with DOACs compared to LMWH (median 116 days versus 34 days). With adherence defined as PDC ≥ 80%, we found no significant difference (95.6% versus 94.6% adherence with DOACs versus LMWH, P = .33). The mean difference of PDC between the two groups was also similar. With medication adherence defined as PDC ≥ 95%, adherence was evident in 73% of DOAC users and 81% of patients on LMWH (P < .001). Prescription copayments were higher on average for LMWH compared to DOACs (mean $153.61 versus 40.67; standard deviation $306.74 versus $33.11). Conclusion Patients remain on DOACs longer than LMWH, but medication adherence is similar with LMWH.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Schaefer JK, Li M, Wu Z, et al. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. J Thromb Haemost. 2020. PMID: 33104289. doi:10.1111/jth.15153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。